QUANTITATIVE DETERMINATION AND VALIDATION OF ETORICOXIB AND PARACETAMOL COMBINED TABLET DOSAGE FORM BY REVERSE PHASE-HPLC

Abstract

An RP-HPLC technique was used to produce a cost-effective simultaneous quantification of Etoricoxib and Paracetamol in combined pharmaceutical tablet dosage forms. The approach was validated for Etoricoxib and Paracetamol using ICH recommendations over a range of 20-120ppm and 20-200ppm, respectively. At a temperature of 250 C±0.50 C, an analytical column PURITAS™ EXIMIUS C18, 250mmx4.6mm, 5 microns was utilized. At a flow rate of 1.0 ml/min, the mobile phase was acetonitrile and 0.1 percent acetic acid in water in a 70:30V/V ratio. The elution was examined using a PDA detector with a detection wavelength of 235nm. The retention times for Etoricoxib and paracetamol are 4.2 and 2.1 minutes, respectively. The percentage recoveries for Etoricoxib and paracetamol were 98.28% and 102.1%, respectively. The RSD values are not greater than 2%.